• Je něco špatně v tomto záznamu ?

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

K. Machova Polakova, H. Zizkova, J. Zuna, E. Motlova, L. Hovorkova, A. Gottschalk, I. Glauche, J. Koblihova, P. Pecherkova, H. Klamova, M. Stastna Markova, D. Srbova, A. Benesova, V. Polivkova, T. Jurcek, D. Zackova, J. Mayer, T. Ernst, FX....

. 2020 ; 34 (8) : 2113-2124. [pub] 20200529

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027980

Grantová podpora
NV16-30186A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 32472084
DOI 10.1038/s41375-020-0882-1
Knihovny.cz E-zdroje

This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n = 17) or scheduled interruption (n = 25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS = 57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS = 20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027980
003      
CZ-PrNML
005      
20231102133250.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-020-0882-1 $2 doi
035    __
$a (PubMed)32472084
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. katerina.machova@uhkt.cz. Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. katerina.machova@uhkt.cz.
245    10
$a Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission / $c K. Machova Polakova, H. Zizkova, J. Zuna, E. Motlova, L. Hovorkova, A. Gottschalk, I. Glauche, J. Koblihova, P. Pecherkova, H. Klamova, M. Stastna Markova, D. Srbova, A. Benesova, V. Polivkova, T. Jurcek, D. Zackova, J. Mayer, T. Ernst, FX. Mahon, S. Saussele, I. Roeder, NCP. Cross, A. Hochhaus,
520    9_
$a This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n = 17) or scheduled interruption (n = 25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS = 57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS = 20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bcr-abl fúzové proteiny $x genetika $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $x mortalita $7 D015464
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a reziduální nádor $7 D018365
650    _2
$a polymerázová řetězová reakce $x metody $7 D016133
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a tyrosinkinasy $x antagonisté a inhibitory $7 D011505
650    _2
$a messenger RNA $x analýza $7 D012333
650    _2
$a indukce remise $7 D012074
650    _2
$a nenasazení léčby $7 D028761
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zizkova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Zuna, Jan $u CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Motlova, Eliska $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Hovorkova, Lenka $u CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Gottschalk, Andrea $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany.
700    1_
$a Glauche, Ingmar $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany.
700    1_
$a Koblihova, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Pecherková, Pavla, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1980- $7 ctu2013787641
700    1_
$a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Stastna Markova, Marketa $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Srbova, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Benesova, Adela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Polivkova, Vaclava $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Jurcek, Tomas $u Center of Molecular Biology and Gene Therapy, Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Zackova, Daniela $u Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Mayer, Jiri $u Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Ernst, Thomas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany.
700    1_
$a Mahon, Francois X $u BERGONIE Institute BORDEAUX, INSERM U1218 University of Bordeaux, Bordeaux, France.
700    1_
$a Saussele, Susanne $u Department of Haematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
700    1_
$a Roeder, Ingo $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
700    1_
$a Cross, Nicholas C P $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury and Faculty of Medicine, University of Southampton, Southampton, UK.
700    1_
$a Hochhaus, Andreas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 34, č. 8 (2020), s. 2113-2124
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32472084 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20231102133244 $b ABA008
999    __
$a ok $b bmc $g 1608315 $s 1119160
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 8 $d 2113-2124 $e 20200529 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
GRA    __
$a NV16-30186A $p MZ0
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace